Brief: BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn in ALS
20/11/2023 13:15
Nov 20 (Reuters) - Brainstorm Cell Therapeutics Inc
BCLI.O :
* BRAINSTORM CELL THERAPEUTICS ANNOUNCES IN-PERSON MEETING
WITH
THE FDA TO DISCUSS CONFIRMATORY PHASE 3 TRIAL FOR NUROWN® IN ALS
* BRAINSTORM CELL THERAPEUTICS INC - MEETING WILL TAKE PLACE
ON
DECEMBER 6; COMPANY PLANS TO SEEK SPECIAL PROTOCOL ASSESSMENT
(SPA)
Source text for Eikon: ID:nPn6VRJrNa
Further company coverage: BCLI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brainstorm Cell Therapeutics
See all newsBrief: Brainstorm Appoints Former FDA Associate Commissioner Peter J. Pitts As Executive Chairman
Brief: Brainstorm Cell Therapeutics Announces First Quarter 2026 Financial Results And Provides Corporate Update
Brief: Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing At Premium To Market
Brief: Brainstorm Cell Therapeutics Announces Second Quarter Financial Results
Brainstorm Cell Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview